Rheumatic Endocarditis: o o o o o
Rheumatic Endocarditis: o o o o o
Rheumatic Endocarditis: o o o o o
INCIDENCE
The incidence of rheumatic fever in the United States and other developed countries is
believed to have steadily decreased, but the exact incidence is difficult to determine
because the infection may go unrecognized and patients may not seek treatment. As many
as 39% of patients with rheumatic fever develop various degrees of rheumatic heart
disease associated with valvular insufficiency, heart failure, and death. The disease also
affects all bony joints, producing polyarthritis. The prevalence of rheumatic heart
disease is difficult to determine because clinical diagnostic criteria are not standardized
and autopsies are not routinely performed. Except for rare outbreaks, the prevalence of
rheumatic heart disease in the United States is believed to be less than 0.05 cases per
1000 people. The number of U.S. citizens who die from rheumatic heart disease declined
from approximately 15,000 in 1950 to about 4,000 in 2001.
CLINICAL MANIFESTATIONS
Symptoms of streptococcal pharyngitis may precede rheumatic symptoms
o Sudden onset of sore throat; throat reddened with exudate
o Swollen, tender lymph nodes at angle of jaw
o Headache and fever 101° F to 104° F (38.9° C to 40° C)
o Abdominal pain (children)
o Some cases of streptococcal throat infection are relatively asymptomatic
Warm and swollen joints (polyarthritis)
Chorea (irregular, jerky, involuntary, unpredictable muscular movements)
Erythema marginatum (transient meshlike macular rash on trunk and extremities in
about 10% of patients)
Subcutaneous nodules (hard, painless nodules over extensor surfaces of
extremities; rare)
Fever
Prolonged PR interval demonstrated by ECG
Heart murmurs; pleural and pericardial rubs
MEDICAL MANAGEMENT
Antimicrobial therapy penicillin is the drug of choice
o Note that missed doses of antibiotics due to the patient's unavailability
while off the unit for diagnostic tests are given after return to the unit.
o Missed antibiotic doses may have irreversible deleterious consequences.
o Notify health care provider if doses will be missed to make sure that
appropriate alternative measures are taken.
Salicylates or NSAIDs to control fever and pain if present
Prevention of recurrent episodes through long-term penicillin therapy for 5 years
after initial attack in most adults; periodic prophylaxis throughout life if valvular
damage
PATHOPHYSIOLOGY
The heart damage and the joint lesions of rheumatic endocarditis are not infectious in the
sense that these tissues are not invaded and directly damaged by destructive organisms;
hemolytic streptococci. Leukocytes accumulate in the affected tissues and form nodules,
myocarditis develops, which temporarily weakens the contractile power of the heart. The
pericardium also is affected, and rheumatic pericarditis occurs during the acute illness.
These myocardial and pericardial complications usually occur without serious sequelae.
Rheumatic endocarditis, however, results in permanent and often crippling side effects.
Patients who have Rheumatic Endocarditis and whose valvular dysfunction is mild may
require no further treatment. Nevertheless, the danger exist for recurrent attacks of
acute Rheumatic fever, bacterial Endocarditis, embolism from vegetations or mural
thrombi in the heart, and eventually cardiac failure. The nurse monitors the patient for
signs and symptoms of valvular disease, heart failure, pulmonary hypertension,
thromboemboli and dysrhythmias.
NURSING MANAGEMENT:
Teach patients about the disease, its treatment, and the preventive steps needed
to minimize recurrence and potential complications.
After active treatment with antibiotics, patients must take prophylactic antibiotics
on a regular schedule and before invasive procedure.
Have a long-term cardiac reevaluation to maintain hydration, and to report any signs
of thromboemboli or heart failure to health care providers.
In mild cases, it may require no further treatment but still, the nurse monitors the
patient for signs and symptoms of valvular disease, heart failure, pulmonary
hypertension, thromboemboli and dysrhytmias.